Summit Therapeutics Inc.
SMMT
$16.18
$0.060.34%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -387.81% | -368.59% | -361.42% | -107.50% | 64.01% |
| Total Depreciation and Amortization | 64.04% | 29.90% | -4.59% | -35.56% | -55.05% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 1,039.35% | 967.68% | 1,067.92% | 241.87% | -88.18% |
| Change in Net Operating Assets | 102.96% | -9.47% | 17.83% | 31.82% | 3,099.81% |
| Cash from Operations | -127.25% | -138.87% | -112.20% | -84.66% | -85.13% |
| Capital Expenditure | -372.66% | -299.21% | -304.92% | -605.06% | -8.59% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 15.37% | 273.08% | 332.74% | -183.81% | 65.09% |
| Cash from Investing | 15.11% | 272.76% | 332.11% | -184.37% | 65.06% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | 67.55% | -- | -- | -305.09% |
| Issuance of Common Stock | 28.32% | -90.85% | 39.92% | 6,539.74% | 328.87% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 61.99% | -95.11% | -8.08% | 5,540.71% | 340.66% |
| Foreign Exchange rate Adjustments | 666.67% | -96.41% | 34.62% | -84.40% | -102.15% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 256.60% | 105.92% | 2,116.44% | 1,705.40% | 105.85% |